Parkinson's disease (PD) is a growing burden worldwide, and there is no reliable biomarker
used in clinical routines to date. Cerebrospinal fluid (CSF) is routinely collected in patients …

Motivation The emergence of abundant biological networks, which benefit from the
development of advanced high-throughput techniques, contributes to describing and modeling …

Protein-coding variants in the GBA gene modulate susceptibility and progression in ~10%
of patients with Parkinson’s disease (PD). GBA encodes the β-glucocerebrosidase enzyme …

Background The last few years have seen major advances in blood biomarkers for
Alzheimer's Disease (AD) with the development of ultrasensitive immunoassays, promising to …

Frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) are fatal
neurodegenerative diseases that represent ends of the spectrum of a single disease. The most …

Objective To test the relationship between clinically relevant types of GBA mutations (none,
risk variants, mild mutations, severe mutations) and β-glucocerebrosidase activity in patients …

The experience of positive affect during new motherhood is considered essential for a
healthy mother–infant relationship, with life-long consequences for both mother and child. …

Multiple system atrophy (MSA) is a fatal neurodegenerative disease of unknown etiology
characterized by widespread aggregation of the protein alpha-synuclein in neurons and glia. Its …

Background: Associations between phenotypic traits, environmental exposures, and
Parkinson’s disease have largely been evaluated one-by-one, piecemeal, and pre-selections. A …

Parkinson’s disease (PD) is a growing burden worldwide, and despite ongoing efforts to find
reliable biomarkers for early and differential diagnosis, prognosis and disease monitoring, …